A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.

Fyfe, D; Raynaud, F; Langley, R E; Newell, D R; Halbert, G; Gardner, C; Clayton, K; Woll, P J; Judson, I; Carmichael, J

Fyfe, D; Raynaud, F; Langley, R E; Newell, D R; Halbert, G; Gardner, C; Clayton, K; Woll, P J; Judson, I; Carmichael, J.

Affiliation

Fyfe D; CRC Department of Clinical Oncology, Nottingham City Hospital, UK.

Cancer Chemother Pharmacol ; 49(1): 1-6, 2002 Jan.

Article in En | MEDLINE | ID: mdl-11855748

Subject(s)

Amsacrine/analogs & derivatives; Amsacrine/pharmacokinetics; Antineoplastic Agents/pharmacokinetics; Administration, Oral; Adult; Aged; Aged, 80 and over; Amsacrine/administration & dosage; Amsacrine/adverse effects; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle Aged; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Amsacrine / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2002 Document type: Article

Search on Google

XML

PubMed Links